Novartis: A Cohesive Platform for Clinical Trial DHT Regulatory Acceptance
In a highly anticipated session at Panagora Pharma’s 7th Digital Biomarkers in Clinical Trials Summit, Mireille Muller, Executive Director...
Announcing Areti Health’s Monumental Seed Round
Areti Health, a clinical trial recruitment innovator, has secured Preface Ventures and Almaz Capital funding. This investment will support...
Inverna INV724 Antibody Receives Rare Pediatric Disease and Orphan Drug Designations for Neuroblastoma Treatment
Invenra Inc.’s bispecific antibody, INV724, has received Rare Pediatric Disease (RPDD) and Orphan Drug (ODD) Designations from the FDA....
Rafael Holdings and Cyclo Therapeutics Seal Definitive Merger Pact
Rafael Holdings and Cyclo Therapeutics announce their merger to advance the development of Trappsol® Cyclo™ for treating Niemann-Pick Disease...
Catawba Research Unveils New Scientific Advisory Board
Catawba Research, striving to be a leading Contract Research Organization, announced the expansion of its Scientific Advisory Board with...
FDA Approves Pfizer BioNTech COVID KP.2 Omicron Vaccine: A Health Milestone
The U.S. Food and Drug Administration (FDA) has approved Pfizer and BioNTech‘s Omicron KP.2-adapted 2024-2025 Formula COVID-19 vaccine for...
Bayer Phase II Study of Revolutionary New Heart Drug in CKD Patients
Bayer has initiated the ALPINE-1 Phase II clinical trial to investigate BAY3283142, a soluble guanylate cyclase (sGC) activator, as...
Uncommonly Funded Cancer Research Gains Momentum with Accolades
Curebound, a philanthropic organization that funds groundbreaking cancer research, announces significant updates for its grant recipients. The 2021 recipient...
Bristol Myers Squibb Achieves FDA Acceptance for Treatment Option in Hepatocellular Carcinoma
Bristol Myers Squibb has announced the acceptance by the U.S. Food and Drug Administration (FDA) of its application for...
Novartis New Mobility Digital Biomarker in Clinical Trials
The 7th Annual Digital Biomarkers in Clinical Trials conference featured a compelling presentation by Tilo Hache, Director of Strategy...